Literature DB >> 9077718

The effects of oral doses of lansoprazole and omeprazole on gastric pH.

K G Tolman1, S W Sanders, K N Buchi, M D Karol, D E Jennings, G L Ringham.   

Abstract

We compared gastric pH values after therapeutic doses of lansoprazole and omeprazole in 17 healthy adult men. The pharmacokinetics of the two drugs were studied. A three-way crossover design compared the effects on gastric pH of 15 and 30 mg lansoprazole and 20 mg omeprazole--each given once daily for 5 days. Ambulatory 24-h intragastric pH levels were measured before dosing, after the first and fifth doses in each period, and 15 days after each dosing period. A positive relationship between the lansoprazole or omeprazole area under the curve (AUCs) and the 24-h mean pH values was found for each regimen. No differences in maximum concentration (Cmax) and AUC were noted from day 1 to day 5 for the two lansoprazole doses. With omeprazole, both Cmax and AUC levels were greater on day 5 than on day 1. All three regimens increased 24-h mean gastric pH, although 30 mg lansoprazole had the most significant effect. The percentage of time that gastric pH was >3, >4, and >5 was also significantly higher with 30 mg lansoprazole. All three regimens were associated with reversible elevations of serum gastrin, which more than doubled at some points. No clinically significant adverse events were documented.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9077718     DOI: 10.1097/00004836-199703000-00003

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  16 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Comparative bioavailability study of two oral omeprazole formulations after single and repeated administrations in healthy volunteers.

Authors:  T Duvauchelle; L Millerioux; V Gualano; E Evene; A Alcaide
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.

Authors:  Tal Lorberbaum; Kevin J Sampson; Jeremy B Chang; Vivek Iyer; Raymond L Woosley; Robert S Kass; Nicholas P Tatonetti
Journal:  J Am Coll Cardiol       Date:  2016-10-18       Impact factor: 24.094

Review 4.  Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.

Authors:  Fabio Baldi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Delayed-release lansoprazole plus naproxen.

Authors:  Monique P Curran; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib.

Authors:  Neil J Parrott; Li J Yu; Ryusuke Takano; Mikiko Nakamura; Peter N Morcos
Journal:  AAPS J       Date:  2016-07-22       Impact factor: 4.009

7.  Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis.

Authors:  Colin W Howden; E David Ballard; Weining Robieson
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

8.  Age-dependent pharmacokinetics of lansoprazole in neonates and infants.

Authors:  Weijiang Zhang; Michael Kukulka; Galen Witt; Debra Sutkowski-Markmann; Janine North; Stuart Atkinson
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 9.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

10.  Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.

Authors:  Manuel Vaz-da-Silva; Ana I Loureiro; Teresa Nunes; Joana Maia; Susana Tavares; Amilcar Falcão; Pedro Silveira; Luis Almeida; Patricio Soares-da-Silva
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.